B · Normal
[Hengrui Medicine: Obtained Drug Clinical Trial Approval Notice] On November 18th, Hengrui Medicine (600276.SH) announced that the company and its subsidiaries have received the "Drug Clinical Trial Approval Notice" approved by the State Food and Drug Administration for HRS-2329 tablets, HRS-6093 tablets, SHR-9839 (sc) for injection, HRS-4642 injection, and adebelimab injection, and will conduct clinical trials in the near future.
A-share announcement express 🕐 2026-11-18 16:59

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet